GILDGilead SciencesSigning up patients
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Ovarian Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 72 (planned)
- Started
- Mar 30, 2026
- Main results expected
- Mar 2028
- Fully finished
- Apr 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To determine the safety and tolerability of TUB-040 in combination with standard ovarian cancer drugs
Measured over: From enrollment until 30 days after last study drug
Maximum Tolerated Dose (MTD) of TUB-040 with standard of care (SOC) treatment
Measured over: Day 1 up to Day 21 of each treatment cycle
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07736937 · record last updated 2026-09-01 · checked 2026-11-09 15:47 UTC